Zepbound (tirzepatide)

The FDA has approved a new weight loss medication called Zepbound. It is very similar to Mounjaro in its mechanisms of action, however Mounjaro is approved for diabetes management whereas Zepbound is approved for management of individuals with a diagnosis of obesity and or overweight.

• Qualifications for Zepbound include a BMI of 27-29.9 with a weight related comorbidity (hypertension,
  dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea or cardiovascular disease) or a BMI of 30
  or greater without a weight related comorbidity.
• 1 in 3 patients taking Zepbound had an average weight loss of 25% of body weight at the highest dose.

Contact us to schedule a consultation today.